S. Riley

Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).

Sanjiv J. Shah, P. Elliott, C. Rapezzi, 2017, Circulation. Heart failure.

Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis

M. Boucher, L. Harnisch, C. Vong, 2021, American Journal of Cardiovascular Drugs.

Endocarditis caused by group A beta-hemolytic Streptococcus in an infant: case report and review.

T. Dermody, A. Kavanaugh-McHugh, S. Riley, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Sanjiv J. Shah, D. Judge, P. Elliott, 2018, The New England journal of medicine.

Oral manifestations of Wegener's granulomatosis: a report of three cases and a literature review.

D. Cohen, I. Bhattacharyya, J. Katz, 2007, Journal of the American Dental Association.

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis

R. Labaudinière, D. Judge, M. Maurer, 2016, Neurology and Therapy.

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

D. Judge, P. García-Pavía, G. Merlini, 2020, European journal of heart failure.